ArticlePreventive medicine2021
Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysis.
Article in Preventive medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Physical and mental health outcomes of COVID-19 induced delay in oncological care: A systematic review.Frontiers in oncology · 2023Pooled it
- Prevention, diagnosis and treatment of cervical cancer: A systematic review of the impact of COVID-19 on patient care.Preventive medicine · 2022Pooled it
- The Short-Term Impact Of COVID-19 Pandemic on Cervical Cancer Screening: A Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2022Pooled it
- Cervical Cancer Screening Activity at an Accredited Centre in Romania, 2018-2025: COVID-19 Disruption, Recovery and the Transition to Primary HPV Testing.Healthcare (Basel, Switzerland) · 2026Article
- Predictors of routine HPV-based cervical cancer screening adoption in federally qualified health centers within a multi-state practice research network 2012-2022: retrospective observational study.BMC primary care · 2026Observational
- Opportunities and challenges encountered in managing cervical cancer during the coronavirus disease 2019 pandemic.Infectious agents and cancer · 2024Review
- Impact of the COVID-19 pandemic on cervical cancer screening participation, abnormal cytology prevalence and screening interval in Catalonia.Frontiers in oncology · 2024Article
- Article
- Scoping review of modelling studies assessing the impact of disruptions to essential health services during COVID-19.BMJ open · 2023Article
- Potential global loss of life expected due to COVID-19 disruptions to organised colorectal cancer screening.EClinicalMedicine · 2023Article
- Managing an extension of screening intervals: Avoiding boom and bust in health care workloads.International journal of cancer · 2023Article
- Article
- Clinician practices, knowledge, and attitudes regarding primary human papillomavirus testing for cervical cancer screening: A mixed-methods study in Indiana.Preventive medicine reports · 2023Article
- Observational
- Article
- COVID-19 disruption to cervical cancer screening in England.Journal of medical screening · 2022Article
- Evaluating and Improving Cancer Screening Process Quality in a Multilevel Context: The PROSPR II Consortium Design and Research Agenda.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- Conceptual Framework for Cancer Care During a Pandemic Incorporating Evidence From the COVID-19 Pandemic.JCO global oncology · 2022Review
- Health impacts of COVID-19 disruptions to primary cervical screening by time since last screen: A model-based analysis for current and future disruptions.medRxiv : the preprint server for health sciences · 2022Article
- Cervical Cancer Prophylaxis-State-of-the-Art and Perspectives.Healthcare (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
COVID-19 has disrupted cervical screening in several countries, due to a range of policy-, health-service and participant-related factors. Using three well-established models of cervical cancer natural history adapted to simulate screening across four countries, we compared the impact of a range of standardised screening disruption scenarios in four countries that vary in their cervical cancer prevention programs. All scenarios assumed a 6- or 12-month disruption followed by a rapid catch-up of missed screens. Cervical screening disruptions could increase cervical cancer cases by up to 5-6%. In all settings, more than 60% of the excess cancer burden due to disruptions are likely to have occurred in women aged less than 50 years in 2020, including settings where women in their 30s have previously been offered HPV vaccination. Approximately 15-30% of cancers predicted to result from disruptions could be prevented by maintaining colposcopy and precancer treatment services during any disruption period. Disruptions to primary screening had greater adverse effects in situations where women due to attend for screening in 2020 had cytology (vs. HPV) as their previous primary test. Rapid catch-up would dramatically increase demand for HPV tests in 2021, which it may not be feasible to meet because of competing demands on the testing machines and reagents due to COVID tests. These findings can inform future prioritisation strategies for catch-up that balance potential constraints on resourcing with clinical need.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.